People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Other Health Care, Pharmaceuticals, Biotechnology, Business Services, Retailing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VeraDermics, Inc | — | Other Health Care | Series D+ | $239.3M | $1.0B | 2025 |
| Rivus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $223.5M | $416.3M | 2019 |
| SutroVax, Inc. | — | Biotechnology | Series D+ | $205.9M | $4.5B | 2017 |
| BioAge Labs, Inc. | — | Biotechnology | Series D+ | $194.4M | $2.4B | 2024 |
| Cardiodx Inc | — | Biotechnology | Series C | $174.0M | $742.4M | 2011 |
| Vera Therapeutics, Inc. | — | Biotechnology | Series C | $70.7M | $2.6B | 2020 |
| Stichting Administratiekantoor syncreon | — | Business Services | Series B | $27.4M | $167.5M | 2020 |
| Infacare Pharmaceutical Corp | — | Pharmaceuticals | Series A | $26.7M | $108.4M | 2013 |
| Rock Starr LLC | — | Retailing | Seed | $2.1M | $13.1M | 2015 |
| Rockpoint LLC | — | Retailing | Pre-Seed | $995K | $7.8M | 2017 |
Patrick Enright at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Patrick Enright on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kurt Von Emster | 2 | 6 |
| Bruce Yap | 2 | 2 |
| Peter Barrett | 1 | 18 |
| Beth Seidenberg | 1 | 15 |
| Brook Byers | 1 | 13 |
| Patrick Heron | 1 | 11 |
| Michael Goldberg | 1 | 11 |
| Risa Stack | 1 | 9 |
| Vijay Pande | 1 | 9 |
| James Healy | 1 | 8 |
| Patrick G. Enright | 1 | 7 |
| Derek DiRocco | 1 | 7 |
| Patrick J. Heron | 1 | 7 |
| Peter Hirth | 1 | 7 |
| William Ericson | 1 | 6 |
| James R. Tobin | 1 | 6 |
| Dan Burns | 1 | 6 |
| Dov Goldstein | 1 | 6 |
| Maha Katabi | 1 | 6 |
| SCOTT MORRISON | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.